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Abstract
Zellweger spectrum disorders (ZSDs) represent the major subgroup within the peroxisomal biogenesis disorders caused
by defects in PEX genes. The Zellweger spectrum is a clinical and biochemical continuum which can roughly be divided
into three clinical phenotypes. Patients can present in the neonatal period with severe symptoms or later in life during
adolescence or adulthood with only minor features. A defect of functional peroxisomes results in several metabolic
abnormalities, which in most cases can be detected in blood and urine. There is currently no curative therapy, but
supportive care is available. This review focuses on the management of patients with a ZSD and provides
recommendations for supportive therapeutic options for all those involved in the care for ZSD patients.
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Background
The Zellweger spectrum disorders (ZSDs) are a
heterogeneous group of autosomal recessive disorders
characterized by a defect in peroxisome formation
and are caused by mutations in one of 13 PEX genes
[1–3]. Because of the defect in peroxisome formation,
multiple metabolic (both catabolic and anabolic) pathways
are impaired resulting in metabolic abnormalities. Typic-
ally, ZSD patients accumulate very long chain fatty acids
(VLCFAs), phytanic- and pristanic acid, C27-bile acid
intermediates and pipecolic acid in plasma and have a
deficiency of plasmalogens in erythrocytes [4]. Clinically,
ZSDs are highly heterogeneous, but the core features are:
liver dysfunction, developmental delay and other neuro-
logical abnormalities, adrenocortical dysfunction and
hearing- and vision impairment [5]. Before the biochem-
ical and molecular basis of ZSDs was known, they were
clinically described as three distinct disorders: Zellweger
syndrome (ZS), neonatal adrenoleukodystrophy (NALD)
and infantile Refsum disease (IRD). These phenotypes are
currently recognized as presentations within a clinical
spectrum (with ZS being at the most severe end of the
spectrum) which are now collectively referred to as ZSDs,
in order to appreciate the wide variations in presentation
[6]. Recently, Heimler syndrome was recognized as a
peroxisome biogenesis disorder within the Zellweger
spectrum and added to the (very) mild end of the clinical
spectrum [7]. This review provides a clinical overview of
Zellweger spectrum disorders and focuses on manage-
ment of patients with a ZSD. New developments in the
field of management are discussed.
Disease names and synonyms
Zellweger spectrum disorder/Zellweger syndrome
spectrum/Zellweger syndrome/neonatal adrenoleuko-
dystrophy/infantile Refsum disease/Heimler syndrome
(ORPHA79189).
History and definition
Bowen et al. described a syndrome with failure to thrive,
congenital glaucoma and craniofacial dysmorphic features
with early death (before 2 years of age) [5]. In 1965 Smith
et al. described two siblings with comparable multiple
congenital malformations, but also polycystic kidneys and
intrahepatic biliary dysgenesis [8]. In 1967 Passarge et al.
introduced the term cerebro-hepato-renal syndrome.
Since Hans Zellweger, a pediatrician, contributed two of
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the originally described patients it was later called
Zellweger syndrome [9]. It was not until 1973 that the
causal link between ZS and peroxisomes was made, when
Goldfischer et al. described the absence of peroxisomes in
hepatocytes and renal proximal tubules [10]. Although the
clinical presentation is different, the discovery of similar
biochemical abnormalities revealed that the earlier
described entities infantile Refsum disease and neonatal
adrenoleukodystrophy were also peroxisomal disorders
[11, 12]. Based on these findings, peroxisomes which were
once considered unimportant organelles, were now
connected to a group of diseases and became the object of
intensive scientific investigations. It turned out that perox-
isomes are important organelles in the eukaryotic cell, and
are involved in many catabolic and anabolic metabolic
pathways [4, 13]. At present more than 15 different
peroxisomal disorders have been identified. The genetic
basis of ZSDs has largely been resolved and now includes
13 different PEX genes [14, 15]. The group of diseases is
now referred to as Zellweger spectrum disorders and in-
clude the old disease entities of ZS, NALD, IRD but also
Heimler syndrome which was recently recognized as a
ZSD [7, 16].
Epidemiology
The incidence of ZSDs is estimated to be 1 in 50.000
newborns in the United States [17]. It is presumed that
ZSDs occur worldwide, but the incidence may differ
between regions. For example, the incidence of (classic)
Zellweger syndrome in the French-Canadian region of
Quebec was estimated to be 1 in 12 [18]. A much lower
incidence is reported in Japan, with an estimated
incidence of 1 in 500.000 births [19]. More accurate
incidence data about ZSDs will become available in the
near future, since newborn screening for X-linked
adrenoleukodystrophy (X-ALD) will be implemented in
several countries [20, 21]. The screening method is
based on C26:0-lysophosphatidylcholine (C26:0-lysoPC)
measurement in dried bloodspots using LC-MS/MS
technology, which will also identify ZSD patients [22].
Clinical features
Patients with a ZSD can roughly be divided into three
groups according to the age of presentation: the neonatal-
infantile presentation, the childhood presentation and an
adolescent-adult (late) presentation [23]. An overview of
the main presenting symptoms for these groups is sum-
marized in Fig. 1. The original classification of ZS, NALD
and IRD is less valuable now, especially since additional
variant phenotypes suggestive for a disease spectrum have
been identified. For discussing prognosis and counseling
patients or families this classification may in some cases
still be useful [24].
Neonatal-infantile presentation
ZSD patients within this group typically present in the
neonatal period with hepatic dysfunction and profound
hypotonia resulting in prolonged jaundice and feeding
difficulties. Epileptic seizures are usually present in these
patients. Characteristic dysmorphic features can usually
be found, of which the facial dysmorphic signs are most
evident (Fig. 2a). Sensorineural deafness and ocular
abnormalities like retinopathy, cataracts and glaucoma
are typical but not always recognized at first presenta-
tion. Brain magnetic resonance imaging (MRI) may show
neocortical dysplasia (especially perisylvian polymicro-
gyria), generalized decrease in white matter volume,
delayed myelination, bilaterial ventricular dilatation and
germinolytic cysts [23]. Neonatal onset leukodystrophy
is rarely described [25]. Calcific stippling (chondrodys-
plasia punctata) may be present, especially in the knees
and hips. The neonatal-infantile presentation grossly
resembles what was originally described as classic ZS.
Prognosis is poor and survival is usually not beyond the
first year of life.
Childhood presentation
These patients show a more varied symptomatology
than ZSD patients with a neonatal-infantile presentation.
Presentation at the outpatient clinic usually involves
delayed developmental milestone achievement. Ocular
abnormalities comprise retinitis pigmentosa, cataract
and glaucoma, often leading to early blindness and tun-
nel vision [26]. Sensorineural deafness is almost always
present and usually discovered by auditory screening
programs. Hepatomegaly and hepatic dysfunction with
coagulopathy, elevated transaminases and (history of )
hyperbilirubinemia are common. Some patients develop
epileptic seizures. Craniofacial dysmorphic features are
generally less pronounced than in the neonatal-infantile
group (Fig. 2b, c). Renal calcium oxalate stones and
adrenal insufficiency may develop. Early-onset progres-
sive leukodystrophy may occur, leading to loss of
acquired skills and milestones in some individuals. The
progressive demyelination is diffuse and affects the
cerebrum, midbrain and cerebellum with involvement of
the hilus of the dentate nucleus and the peridentate
white matter [23]. Sequential imaging in three ZSD
patients showed that the earliest abnormalities related to
demyelination were consistently seen in the hilus of the
dentate nucleus and superior cerebellar peduncles,
chronologically followed by the cerebellar white matter,
brainstem tracts, parieto-occipital white matter, splenium
of the corpus callosum and eventually involvement of the
whole of the cerebral white matter [27]. The above de-
scribed rapid progressive leukodystrophy, in combination
with other symptoms described here, resemble what was
originally described as NALD. A small subgroup of
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patients develop a relatively late-onset white matter
disease, but no patients with late-onset rapid progressive
white matter disease after the age of five have been
reported [28]. Prognosis depends on what organ systems
are primarily affected (i.e. liver) and the occurrence of
progressive cerebral demyelination, but life expectancy is
decreased and most patients die before adolescence.
Adolescent-adult presentation
Symptoms in this group are less severe, and diagnosis can
be in late child- or even adulthood [29]. Ocular abnormal-
ities and a sensorineural hearing deficit are the most con-
sistent symptoms. Craniofacial dysmorphic features can
be present, but may also be completely absent (Fig. 2d-f).
Developmental delay is highly variable and some patients
may have normal intelligence. Daily functioning ranges
from completely independent to 24 h care. It is important
to emphasize that primary adrenal insufficiency is com-
mon and is probably under diagnosed [30]. In addition to
some degree of developmental delay, other neurological
abnormalities are usually also present: signs of peripheral
neuropathy, cerebellar ataxia and pyramidal tract signs.
The clinical course is usually slowly progressive, although
the disease may remain stable for (many) years [31].
Slowly progressive, clinically silent leukoencephalopathy is
common, but MRI may be normal in other cases [23].
Etiology and pathophysiology
ZSDs are caused by mutations in one of the 13 different
PEX genes. PEX genes encode proteins called peroxins
and are involved in either peroxisome formation, peroxi-
somal protein import, or both. As a consequence, muta-
tions in PEX genes cause a deficiency of functional
peroxisomes. Cells from ZSD patients either entirely
lack functional peroxisomes, or cells can show a reduced
number of functional peroxisomes or a mosaic pattern
(i.e. a mixed population of cells with functional peroxi-
somes and cells without) [1, 32, 33]. Peroxisomes are
involved in many anabolic and catabolic metabolic pro-
cesses, like biosynthesis of ether phospholipids and bile
acids, α- and β-oxidation of fatty acids and the detoxifi-
cation of glyoxylate and reactive oxygen species.
Dysfunctional peroxisomes therefore cause biochemical
abnormalities in tissues, but also in readily available
materials like plasma and urine [3, 15] (summarized in
Table 1). There is a reasonable genotype-phenotype
correlation [24]. Approximately 60 % of ZSD patients
have biallelic PEX1 mutations and almost 90 different
mutations in PEX1 have been reported so far [34].
Detailed and up to date information about PEX gene
mutations is available through the dbPEX gene database
(http://www.dbpex.org).
Diagnosis
If a ZSD is clinically suspected the first step to confirm
the diagnosis is by biochemical testing in readily accessible
materials like blood and urine. This testing includes meas-
urement of VLCFAs, the peroxisomal bile acid intermedi-
ates di- and trihydroxycholestanoic acid (DHCA, THCA),
the branched-chain fatty acids phytanic and pristanic acid,
Fig. 1 Schematic overview of main presenting symptoms in ZSDs per clinical group
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and pipecolic acid in plasma, plasmalogen levels in eryth-
rocytes, and C26:0-lysoPC in dried blood spots. Addition-
ally, bile acids and oxalic acid can be analyzed in urine
[24]. It is important to note that relatively mild ZSD pa-
tients may have (near) normal biochemical tests in plasma
and urine [35–37]. If clinical suspicion of a ZSD is high
and peroxisomal parameters in blood and urine are nor-
mal, further testing in fibroblasts is recommended,
including culturing the fibroblasts at 40 °C [35]. Further
fibroblast testing is also required to differentiate between
ZSDs and certain peroxisomal single enzyme deficiencies,
and to perform complementation studies to pinpoint the
defective PEX gene. Subsequent mutation analysis of the
defective PEX gene is done in all patients to confirm the
diagnosis. A diagnostic flowchart is provided (Fig. 3). With
increasing availability and reliability of next generation
Fig. 2 Craniofacial dysmorphic features in ZSD patients developing over time a. Photograph of a 6-month-old girl with typical craniofacial dysmorphia.
Note the epicantal folds, high forehead, broad nasal bridge and hypoplastic supraorbital ridges. The anterior fontanel is drawn and enlarged. b-c. Girl
with a ZSD at the age of 9 months (b) and at the age of 1 year and two months (c). Less pronounced facial dysmorphism is present: a high forehead
is seen, a broad nasal bridge, hypoplastic supraorbital ridges, anteverted nares and more subtle epicantal folds. d-f. Photograph of a male with a ZSD
at the age of 5 years (d), 10 years (e) and 15 years (f). No evident facial dysmorphic features can be recognized, although the ears seem to be slightly
low-set. Written informed consent was obtained from the parents of all patients for publication of these images
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sequencing it is possible that genetic tests will become
first tier tests in the future. However, biochemical testing
in blood and/or fibroblasts is still required in these cases
to confirm pathogenicity of the identified mutations and
to characterize the extent of the deficiency.
Differential diagnosis
Differential diagnosis varies with the age of presentation
and most prominent symptoms at presentation (Table 2).
In newborns, ZSDs with hypotonia are most often con-
fused with other conditions presenting with profound
hypotonia including chromosomal abnormalities. The
most important differential disorders to consider when
suspecting a ZSD is the group of single peroxisomal
enzyme deficiencies. Especially Acyl-CoA oxidase type 1
(ACOX1) deficiency and D-bifunctional protein (DBP)
deficiency show great overlap and in some cases,
especially in the neonatal-infantile and childhood period,
can be clinically indistinguishable from ZSDs [38, 39].
Also MRI-features in DBP-deficiency resemble those of
ZSD patients [27]. Differentiation is possible with bio-
chemical and genetic tests as summarized in Table 3.
Dependent on the most prominent presenting symptom
such as retinitis pigmentosa, cerebellar ataxia or adrenal
insufficiency, other single peroxisomal enzyme deficien-
cies like classical Refsum disease, alpha-methylacyl-CoA
racemase deficiency or X-ALD should be considered.
Genetic counseling and antenatal diagnosis
Because of the poor outcome and high disease burden
associated with the majority of ZSDs, genetic counseling
should be offered to parents of affected children. Car-
riers can be offered prenatal- or preimplantation genetic
diagnosis. Before prenatal genetic testing can be per-
formed the familial pathogenic mutation (s) in one of
the PEX genes need (s) to be identified [1]. If the PEX mu-
tations are unknown or cannot be detected, biochemical
prenatal testing for ZSD is possible in chorionic villus
biopsy material, cultured chorionic villus cells or cultured
amniocytes. Biochemical prenatal testing can only be
performed in case of clear biochemical abnormalities in
cells from the index patient [15].
Clinical management and treatment
Because no curative therapy for patients with a ZSD
exists, intervention is supportive and based on symp-
toms. Past- and current supportive therapeutic options
are summarized in Table 4.
Docosahexaenoic acid
Docosahexaenoic acid (DHA; C22:6ω3) is a long-chain
polyunsaturated fatty acid important for retinal and brain
function [40, 41]. Tetracosahexaenoic acid (C24:6ω3)
undergoes one cycle of peroxisomal beta-oxidation to be
converted to DHA [4], leading to reduced levels of DHA
when peroxisomes are absent. Because ZSD patients often
have low levels of DHA in membranes of erythrocytes,
supplementation of DHA was suggested to be a possible
therapy. Although some studies have claimed a beneficial
effect of DHA supplementation [42, 43], a randomized
double-blind placebo controlled trial showed that DHA
treatment leads to increased DHA levels in plasma, but no
improvement of visual function and growth could be
observed [44].
Table 1 Peroxisome functions and their biochemical consequences and possible clinical relevance in ZSDs
Peroxisome function Biochemical consequence Possible clinical relevance
β-oxidation of VLCFA (≥C22) Impaired chain shortening of VLCFA,
last step in DHA synthesis is impaired
Brain, nerve and adrenal damage due to VLCFA
tissue accumulation, DHA deficiency affects brain
function and vision
β-oxidation of methyl-branched chain
fatty acid, DHCA and THCA
Impaired chain shortening of DHCA,
THCA and pristanic acid
Pristanic acid accumulation affects brain function,
accumulation of DHCA and THCA causes liver
toxicity and probably also brain damage
α-oxidation of fatty acids Impaired (pre-) degradation of methyl
branched phytanic acid
Retinal degeneration, brain and nerve damage
due to phytanic acid accumulation
Fatty acid racemization Reduced convertion of pristanoyl-CoA
and C27-bile acyl-CoAs into stereoisomers
before β-oxidation
Tissue accumulation of DHCA, THCA, pristanic- and
phytanic acid
Ether phospholipid (plasmalogen) biosynthesis Impaired formation of ether phospholipids Plasmalogen deficiency gives rise to growth- and
psychomotor retardation, cataract and bone
development anomalies
Glyoxylate detoxification Conversion of glyoxylate into oxalate,
a toxic metabolite
Accumulation leads to calcium oxalate renal stones
L-lysine oxidation Impaired L-pipecolic acid degradation Accumulation of pipecolic acid, no clinical
consequences known [78]
Hydrogen peroxide detoxification Decreased catabolism of hydrogen peroxide Increased reactive oxidant damage
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Lorenzo’s oil
Lorenzo’s oil (i.e. 4:1 mix of glyceryl trioleate and glyceryl
trierucate) therapy was originally developed for the single
peroxisomal enzyme deficiency X-ALD, and was shown to
lower VLCFAs in plasma [45], but had no effect on disease
progression [46, 47]. Some studies reported lowering of
the VLCFA levels in plasma by Lorenzo’s oil in ZS babies
[48, 49]. However, based on data of studies in X-ALD indi-
viduals, there is no reason to expect that Lorenzo’s oil will
be beneficial for ZSD patients at this point.
Cholic acid
Cholic acid is a primary C24 bile acid, involved in for
instance the absorption of fat-soluble vitamins. Cholic
acid is formed from its precursor THCA by one
peroxisomal beta-oxidation cycle. The peroxisomal
C27-bile acid intermediates DHCA and THCA accu-
mulate in ZSDs and are considered to be more toxic
than the primary C24 bile acids due to their altered
physical properties and are believed to contribute to
the liver disease in ZSDs (e.g. dysfunction and liver
Fig. 3 Diagnostic flow-chart for ZSDs. a Very long chain fatty acids: C26:0, C24:0/C22:0 ratio, C26:0/C22:0 ratio. b Single enzyme deficiency with pheno-
typical ZSD similarities like ACOX1 deficiency and DBP deficiency. c Next generation sequencing (NGS) of all PEX genes is advised when complementa-
tion analysis is not practicable
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fibrosis) [50]. The bile acid intermediates are only
partly conjugated and are less well excreted than C24
bile acids contributing to cholestasis. We hypothesize
that DHCA and THCA cross the blood–brain barrier
and cause central nerve system damage. Several case
reports have described a beneficial effect of cholic
acid in ZS babies, supported by reduced urinary and
plasma excretion of DHCA/THCA [51, 52]. Clinically
there was increased growth and an increase in the
levels of fat-soluble vitamins. Furthermore, bile acid
treatment in mice was shown to improve hepatic dis-
ease [53]. Limitations of the studies so far, however,
are the small number of treated patients and short
follow-up. Current evidence is insufficient to conclude
that cholic acid treatment is beneficial for patients
with a ZSD. The Food and Drug Administration
recently approved cholic acid as a safe treatment for
ZSD patients in the United States. However, efficiency
should be demonstrated in large clinical trials before
this treatment can be implemented.
Plasmalogen precursors
Due to a deficiency of the first peroxisomal steps in the
biosynthesis of plasmalogens [54], ZSD patients may
have low levels of plasmalogens. Plasmalogens play a
critical role in cell membranes and as anti-oxidants [55].
It was suggested that supplementation with precursors
of plasmalogens (batyl alcohol) could be beneficial for
ZSD patients, as import of these alkylglycerols proceeds
normally. Several case reports have described an increase
in erythrocyte plasmalogen levels after treatment and
improvement of clinical symptoms in some patients
[56–58]. Although never studied systematically, ether
lipid therapy could be of interest for ZSD.
Citrate
The toxic metabolite oxalate accumulates in plasma
and urine from ZSD patients [4]. This causes renal
calcium oxalate stones. In a large cohort of Dutch
ZSD patients a high prevalence of 83 % of renal
calcium oxalate stones was shown [59]. For this rea-
son, patients should be screened for the presence of high
levels of oxalic acid in urine yearly. To prevent the forma-
tion of renal stones, patients with hyperoxaluria should
start oral citrate treatment. Furthermore, sufficient fluid
intake is recommended [60].
Supportive care
All ZSD patients need to be screened for adrenal
insufficiency [30], epilepsy, low levels of fat-soluble
vitamins, (partly) vitamin K dependent coagulopathy,
high levels of phytanic acid, hearing or visual impair-
ment and enamel hypoplasia. They should be treated
according to the identified abnormalities, e.g. supple-
mentation of cortisone, anti-epileptic drugs, vitamins
and/or a phytanic restricted diet. Because supplemen-
tation of cortisone is associated with severe side
effects, such as growth suppression and osteoporosis
[61], only patients with a true insufficiency (i.e.
altered Synacthen test) should be treated. A phytanic acid
restricted diet is only necessary when levels of phytanic
acid are extremely high and is not recommended when
levels are moderately increased, as sufficient intake of
Table 2 Differential diagnosis of ZSDs based on the most
prominent presenting symptom
Main presenting symptom Differential diagnosis
Hypotonia in newborns Chromosomal abnormalities (Down
syndrome, Prader-Willi syndrome)
Congenital infections (cytomegalovirus,
rubella, herpes simplex, toxoplasmosis)
Hypoxic ischemic encephalopathy
Cerebral malformations
Other metabolic disorders (acid maltase
deficiency, carnitine deficiency,
cytochrome-c-oxidase deficiency)
Other peroxisomal disorders (acyl-CoA
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calories is more decisive. Hearing and visual impair-
ment should be (partly) corrected by hearing aids and
glasses, with ophthalmologic and audiological evalua-
tions yearly. Enamel hypoplasia, present in nearly all
patients, should be followed-up by a dentist [62, 63].
Some patients will need a gastrostomy to provide
adequate intake of calories.
Current/future developments
Several compounds that stimulate peroxisomal biogen-
esis and function in vitro [64–66] were discovered
recently and clinical trials are ongoing (clinicaltrails.gov:
NCT01838941). Hopefully, some of these compounds
will be able to rescue or improve peroxisomal func-
tion in patients. The greatest beneficial effect is
expected in patients whose fibroblasts showed a
temperature sensitivity with worsening of the pheno-
type when cultured at 40 °C and improvement of
peroxisomal functions at 30 °C [67, 68]. In addition
to these new compounds, the effect of cholic acid is
Table 3 Differences in biochemical characteristics of ZSDs and phenotypical similar single enzyme deficiencies
ZSD DBP-D ACOX1-D Remarks
Plasma
Very long chain fatty acidsa ↑b ↑b ↑b False positives possible in ketogenic diets,
hemolyzed samples and peanut rich diet.
Di- and trihydroxycholestanoic acid ↑b N-↑ N
Phytanic acid N-↑ N-↑ N Derived from dietary sources only; dependent
on dietary intake. Normal in newborns.
Pristanic acid N-↑ N-↑ N Derived from dietary sources only (direct and
indirectly via phytanic acid). Normal in newborns.
Erythrocytes
Plasmalogen level ↓-N N N
Blood spot
C26:0 lysophosphatidylcholine ↑ ↑ ↑
Fibroblasts
Plasmalogen synthesis ↓ N N
DHAPAT ↓ N N
Alkyl DHAP synthase ↓ N N
C26:0 β-oxidation ↓ ↓ ↓
Pristanic acid β-oxidation ↓ ↓ N
Acyl-CoA oxidase 1 ↓-N N ↓
D-Bifunctional protein ↓-N ↓ N
Phytanic acid α-oxidation ↓ N N
Phytanoyl CoA hydroxylase ↓ N N
Peroxisomes ↓ N N Peroxisomal mosaicism can be present in ZSD.
In DBP- and ACOX1-deficiency abnormal
peroxisomal morphology may be present.
Mutant gene PEX1,2,3,5,6,10,11β,12,13,14,16,19,26 HSD17B4 ACOX
aVery long chain fatty acids: C26:0, C24:0/C22:0 ratio, C26:0/C22:0 ratio
bMay be minimally abnormal to normal in exceptional cases
Table 4 Supportive therapeutic options in ZSDs
Symptom/disease Treatment/intervention
Adrenal insufficiency Cortisone
Coagulopathy Vitamin K suppletion
Enamel hypoplasia Dentist referral
Epilepsy Standard antiepileptic drugs
Hearing impairment Hearing aids, cochlear implant
High phytanic acid plasma level Phytanic acid restricted diet
Hyperoxaluria Oral citrate treatment Sufficient
fluid intake
Insufficient calory intake Gastrostomy
Low levels of fat-soluble
vitamins (A, D, E)
Vitamin suppletion
Visual impairment Cataract removal, glasses and
ophthalmologist referral
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currently under investigation (controlled-trials.com:
ISRCTN96480891) in a large cohort of ZSD patients.
Although never tested in ZSD patients, gene therapy
with or without tissue specific targeting might be a
potential treatment. Several years ago gene therapy was
already proposed for X-ALD [69]. Although promising,
gene therapy still needs to be optimized to be feasible
for patients [70]. First, studies have to be conducted in
the recently published mild PEX1 mouse model [71],
before a human trial can be initiated.
An orthotopic liver transplantation was described in
a single 6-month old ZSD patient and hepatocytes
transplantation in another 4-year old patient [72, 73].
It resulted in decreased concentrations of VLCFAs
and pipecolic acid, and improved bile acid profiles.
However, the effect on long-term disease course has
not been reported.
Although bone marrow transplantation (BMT) is an
established therapy for the cerebral childhood form of
X-ALD [74], there are no reports describing BMT in
ZSD patients. BMT would be of interest for those
patients who develop leukodystrophy in infancy. However,
with the current knowledge it is impossible to predict
if patients will develop this rapid progressive leuko-
dystrophy. Recently, a retrospective study revealed
that patients with X-ALD still develop an adrenomye-
lopathy phenotype after BMT [75]. Nevertheless,
BMT could possibly be beneficial for a subgroup of
patients within the ZSD spectrum, but first new
techniques/markers that can predict whether or not
patients will develop a severe progressive leukodystro-
phy have to be elucidated.
Prognosis
Although a rough genotype-phenotype correlation exists
for several PEX genes, such as PEX1 and PEX26 [76, 77],
the severity and progression of the disease is difficult to
predict for individual patients. This will become more
relevant as newborn screening is implemented. As a
consequence of newborn screening for X-ALD by C26:0-
lysoPC in several countries ZSD will also be diagnosed
at birth. Children with the severe phenotype (neonatal-
infantile presentation with severe clinical symptoms)
have a poor prognosis and these patients usually die
within the first year of life. Patients that present in child-
hood or adolescence usually have a better prognosis, but
can develop progressive liver disease or leukodystrophy
and deteriorate. If progressive liver disease or leukodys-
trophy occurs prognosis is poor. The remaining milder
individuals can reach adulthood without progression or
with long periods of stabilization. When progression
occurs, it is mainly related to peripheral neuropathy and
pyramidal signs, while cognition remains stable [31].
Unresolved questions
The effect of cholic acid is based upon case reports only,
but within the coming years the clinical effects will be
investigated in larger cohorts. In addition, results of
ongoing trials will be published. An important limitation
to consider when interpreting the data of these trials is
the broad spectrum of severe and milder clinical pheno-
types and associated biochemical variations within these
cohorts. Furthermore, the natural course of the disease
can lead to false conclusions, as peroxisomal metabolites
were shown to fluctuate and decline with age [31]. A large
prospective natural history study is therefore needed. We
and others, recently started collecting the data of a large
prospective cohort of ZSD patients (clinicaltrails.gov:
NCT01668186).
Second, plasma levels of peroxisomal metabolites do
not correlate well with disease severity, as they generally
decrease with age. Furthermore, therapies like DHA and
Lorenzo’s oil improved plasma levels of DHA and C26:0,
albeit no effect on the clinical phenotype has been
observed. This is possibly related to differences in ex-
pression or activity of peroxisomes in the targeted tissue.
Therefore, using plasma levels as a surrogate outcome in
clinical trials is not recommended. New biochemical
outcome parameters that correlate with disease progres-
sion are necessary, such as analysis of markers for
peroxisomal dysfunctions in lymphocytes.
The pathophysiology of ZSD is still poorly understood.
Similar to the cerebral form of X-ALD, it is still not clear
when or why ZSD patients develop severe rapid progres-
sive leukodystrophy. The recently constructed mild
PEX1 mouse model [71] and natural history studies will
help to answer these questions.
Conclusions
Because of the recently implemented newborn screening,
more medical doctors in different specialties (e.g. pediatri-
cians, clinical geneticist and neurologists) will encounter
patients with a ZSD. ZSDs are clinically heterogeneous
with high morbidity in almost all patient and mortality in
some. Although treatment is currently only symptomatic,
it is important to initiate proper supportive therapy to
improve quality of life of these patients.
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